

Bruce A Sullenger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4843710/publications.pdf>

Version: 2024-02-01

74
papers

3,718
citations

186209

28
h-index

133188

59
g-index

77
all docs

77
docs citations

77
times ranked

4065
citing authors

#	ARTICLE	IF	CITATIONS
1	Aptamers as Therapeutics. <i>Annual Review of Pharmacology and Toxicology</i> , 2017, 57, 61-79.	4.2	383
2	Antidote-mediated control of an anticoagulant aptamer in vivo. <i>Nature Biotechnology</i> , 2004, 22, 1423-1428.	9.4	318
3	Emerging clinical applications of RNA. <i>Nature</i> , 2002, 418, 252-258.	13.7	304
4	From the RNA world to the clinic. <i>Science</i> , 2016, 352, 1417-1420.	6.0	225
5	Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1610-1613.e7.	1.5	215
6	Group II Introns Designed to Insert into Therapeutically Relevant DNA Target Sites in Human Cells. <i>Science</i> , 2000, 289, 452-457.	6.0	203
7	Design of therapeutic biomaterials to control inflammation. <i>Nature Reviews Materials</i> , 2022, 7, 557-574.	23.3	187
8	Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells. <i>Nature Medicine</i> , 1996, 2, 643-648.	15.2	125
9	Nucleic acid-binding polymers as anti-inflammatory agents. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 14055-14060.	3.3	122
10	Development of universal antidotes to control aptamer activity. <i>Nature Medicine</i> , 2009, 15, 1224-1228.	15.2	108
11	Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 4761-4766.	3.3	108
12	Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. <i>Nature Biotechnology</i> , 1997, 15, 41-45.	9.4	95
13	Nucleic acid scavengers inhibit thrombosis without increasing bleeding. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 12938-12943.	3.3	92
14	Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. <i>Journal of NeuroInterventional Surgery</i> , 2021, 13, 202-206.	2.0	75
15	Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function. <i>Nature Medicine</i> , 1996, 2, 1386-1389.	15.2	71
16	Conformationally selective RNA aptamers allosterically modulate the β_2 -adrenoceptor. <i>Nature Chemical Biology</i> , 2016, 12, 709-716.	3.9	65
17	Scavenging nucleic acid debris to combat autoimmunity and infectious disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 9728-9733.	3.3	60
18	Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers. <i>Cell Chemical Biology</i> , 2019, 26, 634-644.e3.	2.5	60

#	ARTICLE	IF	CITATIONS
19	In Vivo Selection Against Human Colorectal Cancer Xenografts Identifies an Aptamer That Targets RNA Helicase Protein DHX9. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e315.	2.3	52
20	Nucleic acid scavenging microfiber mesh inhibits trauma-induced inflammation and thrombosis. <i>Biomaterials</i> , 2017, 120, 94-102.	5.7	52
21	Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass. <i>Nature Biotechnology</i> , 2018, 36, 606-613.	9.4	52
22	Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. <i>Molecular Therapy</i> , 2019, 27, 1228-1241.	3.7	52
23	² Fluoro Modification Differentially Modulates the Ability of RNAs to Activate Pattern Recognition Receptors. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 173-182.	2.0	45
24	Targeted Disruption of β -Arrestin 2-Mediated Signaling Pathways by Aptamer Chimeras Leads to Inhibition of Leukemic Cell Growth. <i>PLoS ONE</i> , 2014, 9, e93441.	1.1	43
25	Modulation of the Coagulation Cascade Using Aptamers. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2083-2091.	1.1	42
26	Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. <i>Molecular Therapy</i> , 2018, 26, 1020-1031.	3.7	42
27	Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test. <i>Science Advances</i> , 2021, 7, .	4.7	42
28	DAMPs/PAMPs induce monocytic TLR activation and tolerance in COVID-19 patients; nucleic acid binding scavengers can counteract such TLR agonists. <i>Biomaterials</i> , 2022, 283, 121393.	5.7	34
29	Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 1-9.	2.0	32
30	Potent Anticoagulant Aptamer Directed against Factor IXa Blocks Macromolecular Substrate Interaction. <i>Journal of Biological Chemistry</i> , 2012, 287, 12779-12786.	1.6	28
31	Translation and Clinical Development of Antithrombotic Aptamers. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 147-155.	2.0	26
32	The Inhibition of Anti-DNA Binding to DNA by Nucleic Acid Binding Polymers. <i>PLoS ONE</i> , 2012, 7, e40862.	1.1	22
33	Rapid test to assess the escape of SARS-CoV-2 variants of concern. <i>Science Advances</i> , 2021, 7, eabl7682.	4.7	21
34	Nucleic Acid Scavenging Polymers Inhibit Extracellular DNA-Mediated Innate Immune Activation without Inhibiting Anti-Viral Responses. <i>PLoS ONE</i> , 2013, 8, e69413.	1.1	20
35	PEG-Like Brush Polymer Conjugate of RNA Aptamer That Shows Reversible Anticoagulant Activity and Minimal Immune Response. <i>Advanced Materials</i> , 2022, 34, e2107852.	11.1	19
36	Aptamers as Reversible Sorting Ligands for Preparation of Cells in Their Native State. <i>Cell Chemical Biology</i> , 2020, 27, 232-244.e7.	2.5	18

#	ARTICLE	IF	CITATIONS
37	Controlling cancer-induced inflammation with a nucleic acid scavenger prevents lung metastasis in murine models of breast cancer. <i>Molecular Therapy</i> , 2021, 29, 1772-1781.	3.7	18
38	Colocalizing ribozymes with substrate rnas to increase their efficacy as gene inhibitors. <i>Applied Biochemistry and Biotechnology</i> , 1995, 54, 57-61.	1.4	17
39	Probing the Interplay between the Two Steps of Group I Intron Splicing: A Competition of Exogenous Guanosine with I%Gâ€. <i>Biochemistry</i> , 1998, 37, 18056-18063.	1.2	17
40	The Nucleic Acid Scavenger Polyamidoamine Third-Generation Dendrimer Inhibits Fibroblast Activation and Granulation Tissue Contraction. <i>Plastic and Reconstructive Surgery</i> , 2014, 134, 420e-433e.	0.7	15
41	Probing the Coagulation Pathway with Aptamers Identifies Combinations that Synergistically Inhibit Blood Clot Formation. <i>Chemistry and Biology</i> , 2014, 21, 935-944.	6.2	13
42	An Aptamer for Broad Cancer Targeting and Therapy. <i>Cancers</i> , 2020, 12, 3217.	1.7	13
43	Therapeutic Aptamers: Evolving to Find their Clinical Niche. <i>Current Medicinal Chemistry</i> , 2020, 27, 4181-4193.	1.2	13
44	Histone Deacetylase 7 Inhibition in a Murine Model of Gram-Negative Pneumonia-Induced Acute Lung Injury. <i>Shock</i> , 2020, 53, 344-351.	1.0	12
45	Targeted genetic repair: an emerging approach to genetic therapy. <i>Journal of Clinical Investigation</i> , 2003, 112, 310-311.	3.9	12
46	Enhancing cardiac reprogramming via synthetic RNA oligonucleotides. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 23, 55-62.	2.3	11
47	Breast cancer-derived DAMPs enhance cell invasion and metastasis, while nucleic acid scavengers mitigate these effects. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 1-10.	2.3	11
48	Differential Induction of Immunogenic Cell Death and Interferon Expression in Cancer Cells by Structured ssRNAs. <i>Molecular Therapy</i> , 2017, 25, 1295-1305.	3.7	10
49	IL-10 and class 1 histone deacetylases act synergistically and independently on the secretion of proinflammatory mediators in alveolar macrophages. <i>PLoS ONE</i> , 2021, 16, e0245169.	1.1	10
50	Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study. <i>Anesthesiology</i> , 2022, 137, 67-78.	1.3	8
51	Riboswitches â€” To Kill or Save the Messenger. <i>New England Journal of Medicine</i> , 2004, 351, 2759-2760.	13.9	7
52	Aptamers to Proteins. , 2006, , 131-166.		7
53	Immobilization of nucleic acid binding polymers as anti-inflammatory agent in autoimmunity. <i>Journal of Controlled Release</i> , 2015, 213, e136.	4.8	7
54	RNA-Mediated Reprogramming of Primary Adult Human Dermal Fibroblasts into c-kit⁺ Cardiac Progenitor Cells. <i>Stem Cells and Development</i> , 2015, 24, 2622-2633.	1.1	7

#	ARTICLE	IF	CITATIONS
55	Differential effects of toll-like receptor stimulation on mRNA-driven myogenic conversion of human and mouse fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 2016, 478, 1484-1490.	1.0	7
56	Toll-like receptor activation as a biomarker in traumatically injured patients. <i>Journal of Surgical Research</i> , 2018, 231, 270-277.	0.8	7
57	Ferric Chloride-induced Canine Carotid Artery Thrombosis: A Large Animal Model of Vascular Injury. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	6
58	Targeting DAMPs with nucleic acid scavengers to treat lupus. <i>Translational Research</i> , 2022, 245, 30-40.	2.2	6
59	Aptamers Coming of Age at Twenty-Five. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 119-119.	2.0	5
60	RGEN Editing of RNA and DNA: The Long and Winding Road from Catalytic RNAs to CRISPR to the Clinic. <i>Cell</i> , 2020, 181, 955-960.	13.5	5
61	Î²-Cyclodextrin-containing polymer treatment of cutaneous lupus and influenza improves outcomes. <i>Molecular Therapy</i> , 2022, 30, 845-854.	3.7	5
62	Generation of an anticoagulant aptamer that targets factor V/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples. <i>Cell Chemical Biology</i> , 2022, 29, 215-225.e5.	2.5	5
63	Blocking Adhesion of Sickle Erythrocytes to Endothelial P-Selectin Using an RNA Aptamer.. <i>Blood</i> , 2007, 110, 147-147.	0.6	2
64	Key Pathogenic Factors in Coronavirus Disease 2019â€™Associated Coagulopathy and Acute Lung Injury Highlighted in a Patient With Copresentation of Acute Myelocytic Leukemia: A Case Report. <i>A&A Practice</i> , 2021, 15, e01432.	0.2	1
65	Blocking Complement-Mediated Hemolysis of PNH Erythrocytes by RNA Aptamers to C8 and C9.. <i>Blood</i> , 2004, 104, 2824-2824.	0.6	0
66	Blocking Complement-Mediated Hemolysis Using RNA Aptamers That Bind Complement Component C8.. <i>Blood</i> , 2005, 106, 186-186.	0.6	0
67	Blocking Adhesion of Sickle Erythrocytes to Endothelial Î±VÎ²3 Using RNA Aptamer.. <i>Blood</i> , 2006, 108, 688-688.	0.6	0
68	Effect of PAI-1 Specific RNA Aptamers On Cell Adhesion and Motility.. <i>Blood</i> , 2009, 114, 2135-2135.	0.6	0
69	Laboratory Assessment of Anti-Coagulant Properties of a Von Willebrand Factor Targeted Aptamer. <i>Blood</i> , 2014, 124, 4279-4279.	0.6	0
70	X-Ray Structure of an Anticoagulant RNA Aptamer Bound to Factor Xa. Structural Basis for Its Ability to Disrupt Interactions Between Xa and Va within Prothrombinase. <i>Blood</i> , 2014, 124, 4232-4232.	0.6	0
71	Cell-Free DNA Is Elevated after Acute Arterial Injury in Infants. <i>Blood</i> , 2016, 128, 5002-5002.	0.6	0
72	RNA Aptamer Against FXa Synergizes with FXa Catalytic Site Inhibitors to Effectively and Reversibly Anticoagulate Blood in an Ex Vivo Oxygenator Circuit. <i>Blood</i> , 2016, 128, 3823-3823.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Aptamer Mediated Inhibition of Protein S. Blood, 2016, 128, 4946-4946.	0.6	0
74	Blocking pro-invasive signaling and inflammatory activation in triple-negative breast cancer with nucleic-acid scavengers (NASs).. Journal of Clinical Oncology, 2020, 38, e13096-e13096.	0.8	0